A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors
Conclusions Cobimetinib is generally well tolerated and durable responses were observed in BRAFV600E mutant melanoma patients. Evaluation of cobimetinib in combination with other therapies is ongoing.
We present the first case of this phenomenon in a man. A gray-haired, 80-year-old man presented to dermatology clinic with a 3-cm lock of black hair on his vertex scalp that developed over 1 year. Punch biopsies showed an increase in junctional dendritic melanocytes with rare pagetoid cells and extension along the follicular outer root sheath epithelium and interfollicular epidermis, associated with prominent dendritic melanocytic hyperplasia and pigment-containing melanocytes within the hair bulbs. Although the findings on the biopsies were not diagnostic of melanoma in situ, an irregular interfollicular distribution of m...
We report the estimation of the percentage of stroma (POS) using digital pathology in a large population-ascertained cohort of primary melanomas. Consent was obtained from participants in the Leeds Melanoma Cohort Study to access and sample tumor FFPE blocks. H&E-stained slides were digitally scanned and blocks were sampled for gene expression studies using a tissue microarray needle; this yielded a core of tissue from which RNA was extracted and assayed using Illumina WGDASL.
Background: To evaluate demographic and clinicopathological patterns of melanoma in order to better understand characteristics of these tumors seen in tertiary dermatologic center in Singapore.
Importance: Melanoma is a highly aggressive cancer with extremely poor late stage survival. Those with a previous melanoma diagnosis have a 9-fold increased risk for developing a second primary melanoma compared with the general population. Yet, guidelines for dermatologic follow-up full body skin examinations (FBSEs) after diagnosis of stage I melanoma are ill-defined and vary widely.
Introduction: Spitzoid melanocytic tumors (SMTs) range from benign, borderline, to malignant neoplasms: Spitz nevus (SN), atypical Spitz tumor (AST), and Spitzoid melanoma (SM), respectively. While certain histologic and molecular features appear to predict prognosis, significant ambiguity about their biological behavior remains. Herein, we describe the clinical, histologic, and molecular features of Spitzoid neoplasms seen at our large-volume academic practice and examine the impact of secondary expert pathologic consultation.
Introduction: Immune-checkpoint blockade is a novel, but well-known therapeutic approach when treating metastatic melanoma patients. As immune checkpoint inhibitors cause T-cell activation, autoimmune-mediated or immune-related adverse events (irAE) may occur. We aimed to evaluate retrospectively if there was a correlation between the occurence of irAE and response to pembrolizumab.
Introduction: The incidence of both melanoma and nonmelanoma skin cancer is increasing at an alarming rate, particularly for minority populations. Outcomes are often worse in these populations due to delayed detection and treatment, attributed to barriers such as decreased understanding about skin cancers and limited access to dermatological care from lack of insurance. Uninsured patients make up a smaller fraction of dermatology practices than would be predicted by their prevalence in the population.
Background: The incidence of melanoma and nonmelanoma skin cancer has been increasing in all age groups including children and adolescents. Prior studies in the pediatric population have shown low rates of sun protection behaviors and only modest improvement over the past several decades.
Introduction: There is a widely accepted consensus in the literature that ALM cases are more prevalent in other ethnic racial groups than in Caucasians; however, there seems to be no considerable agreement regarding to what degree. The aim of the present study was to compile the source documents reporting proportions of CMM that are ALM-type in ethnic populations, particularly blacks and Asians/Pacific Islanders (APIs), and to elucidate factors that may be causing the large differences in reported values.
We present a patient with refractory neuropathic pain in a normotrophic spread-scar treated with the injection of BTA. A 47-year-old Caucasian female with a history of invasive melanoma of the left upper arm presented with pain in her excision scar.